Nanoliposomal irinotecan + oxaliplatin + capecitabine + cadonilimab

This is a combination therapy consisting of four distinct agents: 1. **Nanoliposomal irinotecan (nal-IRI)**: A nanoliposomal formulation of irinotecan designed to deliver the drug to the tumor microenvironment for local activation. It's encapsulated with polyethylene glycolated liposome which protects it from circulating protein binding and phagocytosis, enhancing its circulation time[1][5]. 2. **Oxaliplatin**: A platinum-based chemotherapy agent. 3. **Capecitabine**: An oral fluoropyrimidine chemotherapy agent that converts to 5-fluorouracil in the body. 4. **Cadonilimab**: A novel bispecific antibody targeting both PD-1 and CTLA-4 immune checkpoints. It was the world's first approved PD-1/CTLA-4 bispecific antibody (approved in China for recurrent/metastatic cervical cancer)[8][9]. This combination appears to integrate multiple mechanisms of action: topoisomerase inhibition (nanoliposomal irinotecan), DNA crosslinking (oxaliplatin), thymidylate synthase inhibition (capecitabine), and dual immune checkpoint inhibition (cadonilimab). ## Development Status Based on the search results, there is no specific clinical trial mentioned that evaluates this exact four-drug combination. However, components of this combination are being studied: - Nanoliposomal irinotecan combinations are being studied in various cancers including biliary tract cancer (NAPOLI-2 trial)[2][7] and pancreatic cancer[5]. - Cadonilimab is being studied in multiple indications including cervical cancer, gastric cancer, and non-small cell lung cancer[8][9][10]. The specific four-drug combination of nanoliposomal irinotecan + oxaliplatin + capecitabine + cadonilimab does not appear to have established clinical trial data in the provided search results. ## Mechanisms of Action The combination would work through multiple mechanisms: 1. Nanoliposomal irinotecan inhibits topoisomerase I, which is overexpressed in several cancer types including breast, lung, and colorectal cancers[1]. 2. Oxaliplatin forms platinum-DNA adducts that inhibit DNA replication and transcription. 3. Capecitabine is metabolized to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis. 4. Cadonilimab binds to PD-1 and CTLA-4 and blocks PD-1/PD-L1, PD-1/PD-L2, CTLA-4/B7.1, and CTLA-4/B7.2 interactions[9], enhancing anti-tumor immune responses. This multi-modal approach could potentially provide synergistic anti-cancer effects by simultaneously targeting cancer cell division, DNA repair, and immune evasion mechanisms.